Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola
- Address
- Jean Joseph Crocqlaan 15, 1020 Brussels, Belgium
Female Urogenital Diseases and Pregnancy Complications
The Interventional Pediatrics unit is initiating studies that examine how immune‑mediated conditions affect maternal health and fetal outcomes in young patients, aiming to improve diagnostics and therapeutic strategies for pregnancy‑related complications.
- Immune‑mediated uterine inflammation
- Maternal‑fetal pharmacokinetic modeling
- Safety of biologic agents during pregnancy
The site, Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola, collaborates with obstetric specialists to broaden its pediatric scope.
Immune System Diseases
In the realm of immune system diseases, the department conducts pediatric trials evaluating novel biologics for Crohn's disease, seeking to determine treatment effectiveness and safety in children who have not responded to standard therapies.
- Biologic efficacy in pediatric Crohn's
- Pharmacokinetic assessment of new agents
- Long‑term safety monitoring
This work supports the hospital’s mission to advance care for children with chronic inflammatory disorders.
Nervous System Diseases
Researchers are exploring therapeutic options for Dravet syndrome, a severe epileptic encephalopathy, by testing the tolerability and impact of emerging medicines on infant brain function, with the goal of ensuring safety for the youngest patients.
- Safety and tolerability in infants
- Neurodevelopmental outcome measures
- Drug distribution in the central nervous system
The pediatric team at the Brussels hospital leverages cutting‑edge monitoring to protect vulnerable children.
Digestive System and Oral Physiological Phenomena
The unit investigates how intestinal inflammation influences growth and nutrition in children with Crohn's disease, aiming to refine therapeutic approaches that protect the digestive tract.
- Assessment of intestinal healing
- Nutritional status monitoring
- Oral formulation suitability for children
Collaboration with gastroenterology experts enhances the site’s capacity to deliver comprehensive care.
Immune system processes
A broader program examines fundamental immune system processes underlying pediatric inflammatory conditions, seeking biomarkers that predict response to treatment across diseases and underpinning personalized medicine initiatives.
- Biomarker discovery
- Cellular immune profiling
- Correlation of immune markers with clinical outcomes
Ongoing studies at Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola aim to translate laboratory findings into bedside improvements.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 5 of 7 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease | AbbVie Deutschland GmbH & Co. KG | Phase III | Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Epoetin Alfa | 1 | Unknown | 2023-12-21 | 2023-12-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.